Marijuana firm aims to develop cannabis-based drugs for FDA approval

Vireo Health is working on marijuana-based drugs that can be FDA approved.

Vireo Health, a Minnesota company that also owns one of New York’s approved medical marijuana cultivation centers, is developing a “new class of cannabinoid-based drugs,” according to a report by Albany Business Review.

Vireo Health announced last week that it’s developing medicines based on tetrahydrocannabinol (THC) and cannabidiol (CBD), two cannabinoid compounds found in marijuana.

Vireo Health is working with California-based Ligand Pharmaceuticals to use the company’s Captisol technology to help develop the new cannabinoid-based drugs, according to Times Union.

Per Times Union:

Captisol, is a patented agent that makes drug compounds more stable, easier to dissolve and potentially more efficient, according to Vireo CEO Kyle Kingsley.

………..

Vireo’s goal is to incorporate Captisol into cannabinoid-based medicines to create new, patent-protected, FDA-approved forms for the drugs, so they could potentially be taken

...
Rate this article: 
Region: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.